Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals, Inc.

Overview
Date Founded

1998

Headquarters

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, 94080, USA

Type of Company

Public

Employees (Worldwide)

29

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at Sunesis Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Director

Executive Director, Translational Medicine

Executive Director, Project Management

Chief Scientific Officer & Executive Vice President, Research & Development

Senior Vice President, Commercial

Chief Financial Officer & Senior Vice President, Finance & Corporate Development

Vice President, Clinical Operations

Vice President, Finance

Vice President, Quality Assurance, Compliance & Regulatory Affairs

Vice President, Technical Operations

Board of Directors

Venture Partner at 5AM Venture Management LLC

Former Executive Vice President, Chief Financial Officer & Chief Accounting Officer at Sangamo Therapeutics, Inc.

President, Research & Development, Senior Vice President & Chief Scientific Officer at Amarin Corporation Plc

Investment Partner at Bay City Capital LLC

Industry Expert at Pearl Street Venture Funds

Chief Executive Officer at Oncology Venture A/S

Former Chief Medical Officer & Senior Vice President at ZymoGenetics, Inc.

Vice President at Eiger BioPharmaceuticals, Inc.

Paths to Sunesis Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Sunesis Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Aisling Capital Management LP is an American private company headquartered in New York, NY, that operates in several countries. The firm provides investment advice. It was founded in 2015.

Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

JFL Capital Management LLC provides investment services. The company was founded by Joseph C. Lawler on November 24, 2014 and is headquartered in Lakeway, TX.

Recent Transactions
Details Hidden

Sunesis Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Sunesis Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Sunesis Pharmaceuticals, Inc. issued Common Stock

Transaction Advisors
Underwriter

Advised onSunesis Pharmaceuticals, Inc. issued Common Stock

Escrow Agent

Advised onSunesis Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onSunesis Pharmaceuticals, Inc. issued USD Common Stock

Head, Private Equity Practice

Advised onSunesis Pharmaceuticals, Inc. issued USD Common Stock

Director

Advised onSunesis Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onSunesis Pharmaceuticals, Inc. issued Common Stock

Advisors & Consultants
Publicist

Managing Director at Argot Partners LLC

Publicist

Founder & Chief Operating Officer at Argot Partners LLC

Clients

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Key Stats and Financials As of 2018
Market Capitalization
$32.5M
Total Enterprise Value
$29.5M
Earnings Per Share
$-0.75
Revenue
$237K
TEVNet Income
-1.11x
Debt TEV
0.25x
Enterprise Value Sales
124.43x
Total Debt
$7.4M
Total Equity
$3.99M
Net Profit
$-26.6M
EBITDAMargin
-10.8K%
EBITDA
$-25.7M
Non-Profit Donations & Grants
Investments
Details Hidden

SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA.

Investors
Details Hidden

Skyline Ventures invests in outstanding companies in all sectors of the healthcare market, including biotechnology, therapeutics, medical devices, consumables and equipment for life sciences research and healthcare information technology. Most often, they lead or co-lead a company's first institutional venture round, but occasionally have helped found or co-found a company, participated in a LBO or invested in a PIPE transaction. Initial investments range from $7 million to $10 million with a total of $15 million to $35 million over the life of the company. They tend to focus on the San Francisco area but have also invested in Boston, San Diego, Denver, the Midwest and Florida

Details Hidden

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Details Hidden

Bridge Bank, NA provides business banking and financial services to small, middle market, and emerging technology businesses. Its products include growth capital, equipment and working capital credit facilities and treasury management solutions, along with international products and services and financing secured by domestic, government, and foreign receivables. The company was founded on May 14, 2001 and is headquartered in San Jose, CA.

Suppliers
Biogen, Inc. Medical Support Services | San Diego, CA

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Sumitomo Dainippon Pharma Chemicals | Osaka, OS

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacturing, sale, import and export of pharmaceuticals products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment handles the creation of new pharmaceutical products. The Other Business segment division includes food ingredients and additives, chemical products materials, veterinary drugs, and diagnostics. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Takeda Pharmaceutical Co., Ltd. Chemicals | Osaka, OS

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Competitors
BeiGene Ltd. Pharmaceuticals - Beijing, BE

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

AbbVie, Inc. Pharmaceuticals - North Chicago , IL

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Sunesis Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Sunesis Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Sunesis Pharmaceuticals, Inc..